Veliparib (ABT-888)

Catalog No.S1004 Synonyms: NSC 737664

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Size Price Stock Quantity  
In DMSO USD 156 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 42 Publications

9 Customer Reviews

  • (A) OVCAR-8 cells were exposed to the indicated concentrations of FdUrd along with vehicle, 3 μM ABT-888 or 300 nM AZD2281 for 24 h. Following washing, ABT-888 and AZD2281 were re-added to the plates initially exposed to these agents, and cells were cultured in the continued presence of ABT-888 and AZD2281 for 8 d until colonies formed. (B) OVCAR-8 cells were exposed continuously to the indicated agents for 8 d. (C) OVCAR-8 cells treated as in (A) except that the indicated concentrations of ABT-888 were used.

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

    OVCAR-8 cells were plated, treated with indicated concentrations of FdUrd and 3 μM ABT-888 using the exposure schemes depicted in (C) and assayed for clonogenicity (D).

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.


    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046-1051. Veliparib (ABT-888) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

  • Colorimetric poly(ADP-ribose) polymerase (PARP) activity assay showing the relative activity of the PARP-1 enzyme in Raji lymphocyte tumor cells. Results show a highly significant difference in PARP activity in the controls [PBS and dimethyl sulfoxide (DMSO)] compared with 24 h incubation with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281. A significant increase in PARP enzyme activity is shown in DMSO-incubated cells compared with PBS control.* P < 0.05.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

    T47D breast cancer cells were pretreated with indicated concentrations of ABT-888



    Dr.Zhang of Tianjin Medical University. Veliparib (ABT-888) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor ABT-888 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor ABT-888 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.


    David Schrmann from University of Base. Veliparib (ABT-888) purchased from Selleck.

    Caption:  451 Lu is a melanoma cell line with high PARP expression that is resistant to temozolomide.  Treatment with 25 µM ABT-888 greatly increased sensitivity to temozolomide compared to cells without ABT-888 treatment as measured by MTS assay.



    Dr. Steve Reuland from University of Colorado Denver. Veliparib (ABT-888) purchased from Selleck.

  • Effect of ABT-888 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.



    Dr. Xiangbing Meng of University of Iowa. Veliparib (ABT-888) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 NGDj[41McW6jc3WgRZN{[Xl? MnXhN|AhdWmw NHjW[HFKdmirYnn0bY9vKG:oIGDBVnAyKHerdHigSWM2OCCxZjCwMlAxOiEQvF2= MmXxNVk5QDh5NkC=
Capan1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TBWVczKGh? MoT6SG1UVw>? MlvRRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDCVmNCOiCpZX7lJI12fGG2ZXSgbJVu[W5iQ3HwZY4yKGOnbHzzJJdqfGhiSVO1NEBw\iB|OT63JO69VQ>? NWrPUm1COjR|OUizPFM>
UM-SCC1 M1vVU2N6fG:2b4jpZ{BCe3OjeR?= M1uxPVExKM7:TR?= M{TZZlI1KGh? NWi3[WZKWmWmdXPld{B1cGViY3XscEB3cWGkaXzpeJk> NVvYcnlCOjF7MUK2NlA>
FaDu Mlj4R5l1d3SxeHnjJGF{e2G7 MWexNEDPxE1? Ml3ZNlQhcA>? NH\He|JT\WS3Y3XzJJRp\SClZXzsJJZq[WKrbHn0fS=> MmTCNlE6OTJ4MkC=
PC-3 MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHMNVAh|ryP MnTZTY5lfWOnczDhJJNq\26rZnnjZY51KGmwaHnibZRqd25iaX6gZ49td267IH\vdo1ifGmxbtMg M4jlN|IyPTdzOUGy
EoL-1-cell NVrpcXpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXtO4hKSzVyPUGuNFc6QCEQvF2= NFHkVnNUSU6JRWK=
NCI-SNU-5 NVqxSnc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnK1TWM2OD1|LkGyPFQyKM7:TR?= M2fiSHNCVkeHUh?=
BV-173 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPVTWM2OD13LkS1OFA6KM7:TR?= Mn7oV2FPT0WU
HCC1806 Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTVwN{WxO|Mh|ryP NHHPd4ZUSU6JRWK=
COLO-680 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XJeGlEPTB;Nj6yNVQxPiEQvF2= MXzTRW5ITVJ?
HCC2218 M4nuUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTdwN{m3NFQh|ryP NF\nXFNUSU6JRWK=
SK-MEL-24 NHLPW5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTdwOEG5NlQh|ryP M1TrenNCVkeHUh?=
NCI-H720 NHruS5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjyTWM2OD16LkSzOlA{KM7:TR?= NYrRdmFVW0GQR1XS
KASUMI-1 MkPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfNTItKSzVyPUiuPFkzPjZizszN M1TZNnNCVkeHUh?=
HAL-01 NVuxOnpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fB[GlEPTB;OT64PFYzKM7:TR?= NXfaT29uW0GQR1XS
CAL-33 M1q2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4faOWlEPTB;MUCuOFM1KM7:TR?= MoqzV2FPT0WU
SK-MEL-1 MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorMTWM2OD1zMj60OlY{KM7:TR?= Mmn6V2FPT0WU
Ramos-2G6-4C10 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnT4TWM2OD1zMj60O|UzKM7:TR?= MVHTRW5ITVJ?
KY821 NE\TeXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnlSHZtUUN3ME2xNk41QDVizszN Mk\wV2FPT0WU
MN-60 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfMSmpKSzVyPUGzMlU{QDlizszN NVHFW3dSW0GQR1XS
DU-145 MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmG3TWM2OD1zMz65NFU{KM7:TR?= M4LsW3NCVkeHUh?=
EW-3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXjUXhKSzVyPUG0MlU2PjVizszN NV7rN2F3W0GQR1XS
OS-RC-2 M1e4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfHcY9RUUN3ME2xOU46PTh7IN88US=> M4TtSHNCVkeHUh?=
ChaGo-K-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u0ZmlEPTB;MU[uOVMzPSEQvF2= M2DiWXNCVkeHUh?=
DEL NXnKfodMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDuTWM2OD1zNj62O|E4KM7:TR?= M{PQW3NCVkeHUh?=
GP5d NEnr[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TwdGlEPTB;MUeuNFU{KM7:TR?= M4HYXHNCVkeHUh?=
COLO-668 M{fUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\L[JpGUUN3ME2xO{43Ojl2IN88US=> MonwV2FPT0WU
NKM-1 NYD6UoF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTF6LkWxNVkh|ryP Ml[3V2FPT0WU
KYSE-150 NGDDbWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvWWnZKSzVyPUG4Mlk6QDZizszN M2\TeXNCVkeHUh?=
Daoy MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1uzT2lEPTB;MUmuOVY1QSEQvF2= MknRV2FPT0WU
ECC10 MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnpNFBkUUN3ME2yNE44PDV3IN88US=> M4KwdHNCVkeHUh?=
A388 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPNT2dKSzVyPUKxMlkxQTFizszN M2\sbnNCVkeHUh?=
MHH-NB-11 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ|LkGzOlMh|ryP MkjNV2FPT0WU
HCC1937 MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTJ2Lke0OkDPxE1? M2jKUXNCVkeHUh?=
NCI-H1693 NGX1PVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XWT2lEPTB;MkeuNlg6QCEQvF2= NVXaSnY6W0GQR1XS
LB771 M1zXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPNeYxNUUN3ME2yPE45Ozd|IN88US=> NF3UOXZUSU6JRWK=
697 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFy1dmNKSzVyPUK5MlAzOzVizszN MWLTRW5ITVJ?
LU-139 NFXabYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHHTWM2OD1{OT6zO|Q5KM7:TR?= NF;4fFVUSU6JRWK=
EW-13 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJ7LkO4NVQh|ryP NETse2xUSU6JRWK=
MOLT-13 M4\5d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJ7LkO4NVQh|ryP M1S3bnNCVkeHUh?=
L-363 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fx[2lEPTB;MkmuOFc6QCEQvF2= NX\xSlJEW0GQR1XS
EM-2 MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXCN4czUUN3ME2yPU41QTBzIN88US=> MVnTRW5ITVJ?
RS4-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rUfWlEPTB;M{CuOFI1OSEQvF2= NGTsOoFUSU6JRWK=
A2780 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D5XWlEPTB;M{CuO|Q2PyEQvF2= M37wTnNCVkeHUh?=
KU812 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\pfGlEPTB;M{KuN|Y1OiEQvF2= NIjvUJNUSU6JRWK=
COLO-684 M{\rfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\XTWM2OD1|Mz6zOVk6KM7:TR?= MXHTRW5ITVJ?
MFE-280 NUfRU49bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LpVWlEPTB;M{OuN|g5QSEQvF2= MX;TRW5ITVJ?
KG-1 M2LBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX1NIdxUUN3ME2zN{43ODBzIN88US=> NUHVcolpW0GQR1XS
JVM-3 NVqx[I5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[4TWM2OD1|NT61PFY5KM7:TR?= Ml\vV2FPT0WU
MV-4-11 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXj0S4ZpUUN3ME2zOU45PDl7IN88US=> Ml;wV2FPT0WU
LAMA-84 MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLMTWM2OD1|Nj63N|Q2KM7:TR?= MmTaV2FPT0WU
MOLT-16 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTN4Lkm1NkDPxE1? MkDsV2FPT0WU
T47D M3jUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTN5LkewNVgh|ryP NIn5TGFUSU6JRWK=
CAL-54 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jONmlEPTB;M{euPVY3KM7:TR?= M2G3ZXNCVkeHUh?=
SW982 M4jncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVe3VmN{UUN3ME2zPE4xQTl6IN88US=> NYjVRWpoW0GQR1XS
IGROV-1 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LIUmlEPTB;M{muN|MxPCEQvF2= NGP1OlhUSU6JRWK=
HCC1187 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIS3UHdKSzVyPUSxMlI4PzFizszN NGDCfmxUSU6JRWK=
SBC-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;0TWM2OD12MT6zNFY{KM7:TR?= NYfUXHdpW0GQR1XS
KARPAS-45 M2XqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHTTWM2OD12MT60PFE5KM7:TR?= M1;rb3NCVkeHUh?=
MOLT-4 NU\oTm0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHNUppXUUN3ME20Nk4zPTN6IN88US=> M13pT3NCVkeHUh?=
JVM-2 NW\0bIxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTR{LkmyNFch|ryP M3PWW3NCVkeHUh?=
A4-Fuk NVHJXo5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MleyTWM2OD12Mz61OlkyKM7:TR?= MnPlV2FPT0WU
MDA-MB-361 NH;hPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD6bJBmUUN3ME20N{45PDF2IN88US=> NGfFcWFUSU6JRWK=
BALL-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTR|Lkm1N|Ih|ryP NGPMb5dUSU6JRWK=
T98G Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTR2Lki1NVch|ryP MWDTRW5ITVJ?
Mo-T MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvpTWM2OD12NT62N|g6KM7:TR?= NYrF[XRbW0GQR1XS
ALL-PO M2S4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\LbWFOUUN3ME20O{4{PzlzIN88US=> NWXCVWhuW0GQR1XS
NCI-H510A NV;sTI1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Lh[2lEPTB;NEeuPVA{PCEQvF2= M1LiT3NCVkeHUh?=
ML-2 NFH6c|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFuwdpZKSzVyPUS5Mlc5PTZizszN NF\6SmlUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]


Animal Research:


+ Expand
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Formulation: Formulated in solution containing 0.9% NaCl adjusted to pH 4.0
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
0.5% methylcellulose+0.2% Tween 80
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29


CAS No. 912444-00-9
Storage powder
in solvent
Synonyms NSC 737664

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01540565 Completed BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Ovarian Epithelial Tumor|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma National Cancer Institute (NCI) April 9 2012 Phase 2
NCT00553189 Completed Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2007 Phase 1
NCT03289910 Recruiting Acute Myeloid Leukemia|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Atypical Chronic Myeloid Leukemia BCR-ABL1 Negative|Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Myelodysplastic/Myeloproliferative Neoplasm|Myelofibrosis|Polycythemia Vera|Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia National Cancer Institute (NCI) June 8 2018 Phase 2
NCT02595905 Recruiting Breast Carcinoma Metastatic in the Brain|Deleterious BRCA1 Gene Mutation|Deleterious BRCA2 Gene Mutation|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer AJCC v6 and v7|Triple-Negative Breast Carcinoma National Cancer Institute (NCI) July 7 2016 Phase 2
NCT01749397 Active not recruiting Stage IV Fallopian Tube Cancer AJCC v6 and v7|Stage IV Ovarian Cancer AJCC v6 and v7|Stage IV Primary Peritoneal Cancer AJCC v7 National Cancer Institute (NCI) December 7 2012 Phase 1
NCT02163694 Active not recruiting Metastatic Breast Cancer AbbVie August 5 2014 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products5

Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID